A Phase 3 Clinical Study of KW-3357 in Patients With DIC (3357-006)

Kyowa Kirin

Status and phase: Terminated; Phase 3

Conditions: Disseminated Intravascular Coagulation (DIC)

Treatments: Drug: KW-3357

Study type: Interventional

Funder types: Industry

Identifiers

NCT01384409

3357-006

Details and patient eligibility

About

To evaluate the efficacy and safety of KW-3357 with concomitant use of heparin using multi-center, non-comparative, open-label method in patients diagnosed as disseminated intravascular coagulation (DIC) by Japanese Association for Acute Medicine-defined DIC criteria.

Enrollment: 5 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Japanese Association for Acute Medicine-defined DIC criteria score >= 4
• Antithrombin activity <= 70%
• Written informed consent from patient or guardian

Exclusion criteria

• Anamnesis or complication of serious drug allergy
• Serious liver disorder, such as fulminant hepatitis and decompensated cirrhosis
• Pregnant, nursing, or possibly pregnant woman
• Possibility for the promotion of bleeding by concomitant use of heparin

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

KW-3357

Experimental group

Treatment:

Drug: KW-3357